Development of liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmaniasis

Journal of Liposome Research

Volumn 23, Issue 2, 2013, Pages 134-144

  Momeni, Arash ^a,b   Rasoolian, Morteza ^a   Momeni, Amir ^c   Navaei, Ali ^a   Emami, Shahriar ^a   Shaker, Zahra ^d   Mohebali, Mehdi ^e   Khoshdel, Alireza ^d  

^a AMIRKABIR UNIVERSITY OF TECHNOLOGY   (Iran)

^b DALHOUSIE UNIVERSITY   (Canada)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cutaneous leishmaniasis; Freeze drying double emulsion; Glucantime; Liposome; Miltefosine

Indexed keywords

LIPOSOME; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL THERAPY; ARTICLE; ATOMIC FORCE MICROSCOPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG FORMULATION; DRUG SYNTHESIS; ENCAPSULATION; FREEZE DRYING; IN VIVO STUDY; LEISHMANIA MAJOR; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PHASE SEPARATION; PRIORITY JOURNAL; SKIN LEISHMANIASIS; ZETA POTENTIAL;

ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIASIS, CUTANEOUS; LIPOSOMES; MICROSCOPY, ATOMIC FORCE;

EID: 84878438973     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2012.762519     Document Type: Article

References (62)

1. Aguiar MG, Silva DL, Nunan FA, et al. (2009). Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. J Antimicrob Chemother 64:1234-40.
2. Al-Jaser M, El-Yazigi A, Kojan M, Croft SL. (1995). Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis. Antimicrob Agents Chemother 39:516-19.
3. Alving CR. (1983). Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther 22:407-24. (Pubitemid 14201457)
4. Angelico R, Ceglie A, Olsson U, Palazzo G. (2000). Phase diagram and phase properties of the system lecithin-water-cyclohexane. Langmuir 16:2124-32. (Pubitemid 30572983)
5. Black CDV, Watson GJ. (1997). The use of pentostam liposomes in the chemotherapy of experimental leishmaniasis. Trans Royal Soc Trop Med Hyg 71:550-2.
6. Boswell GW, Buell D, Bekersky I. (1998). AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 38:583-92. (Pubitemid 28354895)
7. Carneiro G, Santos DCM, Oliveira MC, et al. (2010). Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res 20:16-23.
8. Carvalheiro M, Jorge J, Eleutério C, et al. (2009). Trifluralin liposomal formulations active against Leishmania donovani infections. Eur J Pharm Biopharm 71:292-6.
9. Chang SC, Kuzmenok O, Chiang SC, Lee ST. (2004). An improved method for detection of Leishmaniaamastigotes by an antibody probe against the small subunit of leishmanialribonucleotidereductase. Parasitol Res 94:243-5. (Pubitemid 39371723)
10. Chapman Jr WL., Hanson WL, Alving CR, Hendricks LD. (1984). Antileishmanial activity of liposome-encapsulated meglumineantimo-nate in the dog. Am J Vet Res 45:1028-30. (Pubitemid 14113845)
11. Chellat F, Merhi Y, Moreau A, Yahia LH. (2005). Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 26:7260-75. (Pubitemid 41133578)
12. Cullis PR, Mayer LD, Bally MB, et al. (1989). Generating and loading of liposomal systems for drug-delivery applications. Adv Drug Deliv Rev 3:267-82. (Pubitemid 19201829)
13. Davidson RN, Scott A, Maini M, et al. (1991). Liposomal amphotericin B in drug-resistant visceral leishmaniasis. The Lancet 337:1061-2.
14. Emilio P. (2009). Current treatment for cutaneous leishmaniasis: a review. Am J Ther 16:178-82.
15. Eue I, Zeisig R, Arndt D. (1995). Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor by U 937 cells. J Cancer Res Clin Oncol 121:350-6.
16. Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LAM. (2004). In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm 30:289-96. (Pubitemid 38451753)
17. Frézard F, Michalick MSM, Soares CF, Demicheli C. (2000). Novel methods for the encapsulation of meglumineantimoniate into liposomes. Braz J Med Biol Res 33:841-6. (Pubitemid 30604766)
18. Jass J, Tjärnhage T, Puu G. (2003). Atomic force microscopy imaging of liposomes. Methods Enzymol 367:199-213. (Pubitemid 37337835)
19. Khatami A, Firooz A, Gorouhi F, Dowlati Y. (2007). Treatment of acute old world cutaneous leishmaniasis: a systemic review of the randomized controlled trials. J Am Acad Dermatol 57:335.e1-29.
20. Krause G, Kroeger A. (1994). Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Trans Royal Soc Trop Med Hyg 88:92-4. (Pubitemid 24068862)
21. Layegh P, Pezeshkpoor F, Soruri AH, et al. (2009). Efficacy of cryotherapy versus intralesionalmeglumineantimoniate (glucantime) for treatment of cutaneous leishmaniasis in children. Am J Trop Med Hyg 80:172-5.
22. Maiti S, Dey P, Sa B, Ray S. (2010). Influence of microenvironmental pH of alginate facilitated ethyl cellulose microspheres on entrapment efficiency and release characteristics of fluconazole. Int J Curr Pharm Res 2:17-23.
23. Meyerhoff A. (1999). US food and drug administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 28:42-8. (Pubitemid 29246123)
24. Minodier P, Parola P. (2007). Cutaneous leishmaniasis treatment. Travel Med Infect Dis 5:150-8. (Pubitemid 46585958)
25. Modabber F, Buffet PA, Torreele E, et al. (2007). Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biology and Disease, 6:3 (24 April 2007).
26. Momeni AZ, Aminjavaheri M. (1994). Clinical pictures of cutaneous leishmaniasis in Isfahan. Iran Int J Dermatol 33:260-5. (Pubitemid 24137623)
27. Momeni A, Mohammadi MH. (2009). Respiratory delivery of theophyl-line by size-targeted starch microspheres for treatment of asthma. J Microencapsul 26:701-10.
28. New RCC, Chance ML, Thomas SC, Peters W. (1978). Antileishmanial activity of antimonials entrapped in liposomes. Nature 272:55-6. (Pubitemid 8285567)
29. Oussoren C, Storm G. (1998). Targeting to lymph nodes by subcutaneous administration of liposomes. Int J Pharm 162:39-44. (Pubitemid 28166088)
30. Oussoren C, Storm G. (1999). Role of macrophages in the localisation of liposomes in lymph nodes after subcutaneous administration. Int J Pharm 183:37-41. (Pubitemid 29248825)
31. Oussoren C, Storm G. (2001). Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 50:143-56. (Pubitemid 32727280)
32. Oussoren C, Zuidema J, Crommelin DJA, Storm G. (1997). Lymphatic uptake and biodistribution of liposomes after subcutaneous injection II: influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta 1328:261-72. (Pubitemid 27376453)
33. PanizMondolfi AE, Stavropoulos C, Gelanew T, et al. (2011). Successful treatment of old world cutaneous leishmaniasis due to L. infantum with Posaconazole. Antimicrob Agents Chemother 55:1774-6.
34. Papagiannaros A, Bories C, Demetzos C, Loiseau PM. (2005). Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomed Pharmacother 59:545-50. (Pubitemid 41820384)
35. Papagiannaros A, Hatziantoniou S, Dimas K, et al. (2006). A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines. Biomed Pharmacother 60:36-42. (Pubitemid 41821217)
36. Pavelić Z, Skalko-Basnet N, Filipović-Grčić J, et al. (2005). Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J Control Release 106:34-43. (Pubitemid 41140079)
37. Rao LS. (1986). Anti-leishmanial pharmaceutical formulations. US Patent 4, 594, 241.
38. Reed SG, Barrel-Netto M, Inverso JA. (1984). Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes. J Immunol 132:3116-19. (Pubitemid 14104279)
39. Reithinger R, Dujardin JC, Louzir H, et al. (2001). Cutaneous Leishmaniasis. Lancet Infect Dis 7:581-96.
40. Ribeiro RR, Moura EP, Pimentel VM, et al. (2008). Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate. Antimicrob Agents Chemoter 52:2564-72. (Pubitemid 351915689)
41. Sadeghian G, Ziaei H, Shirani-Bidabadi L, Nilforoushzadeh MA. (2010). Lupoidleishmaniasis due to Leishmania major with remaining large scars: report of 2 cases. East Mediterr Health J 16:344-5.
42. Schettini DA, Costa Val AP, Souza LF, et al. (2005). Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome encapsulated meglumineantimoniate. Braz J Med Biol Res 38:1879-83. (Pubitemid 43078618)
43. Schettini DA, Ribeiro RR, Demicheli C, et al. (2006). Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size. Int J Pharm 315:140-7. (Pubitemid 44275230)
44. Shailesh S, Neelam S, Sandeep K, Gupta GD. (2009). Liposomes: a review. J Pharm Res 2:1163-67.
45. Sharma A, Sharma US. (1997). Liposomes in drug delivery: progress and limitations. Int J Pharm 154:123-40. (Pubitemid 27351317)
46. Shmeeda H, Even-Chen S, Honen R, et al. (2003). Enzymatic assays for quality control and pharmacokinetics of liposome formulations: comparison with nonenzymatic conventional methodologies. Methods Enzymol 367:272-92. (Pubitemid 37337839)
47. Sindermann H, Croft SL, Engel KR, et al. (2004). Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol Immunol 193:173-80. (Pubitemid 40063681)
48. Sindermann H, Engel J. (2006). Development of miltefosine as an oral treatment for leishmaniasis. Trans Royal Soc Trop Med Hyg 100:17-20.
49. Sriamornsak P, Thirawong N, Nunthanid J, et al. (2008). Atomic force microscopy imaging of novel self-assembling pectin-liposome nanocomplexes. Carbohydr Polym 71:324-9. (Pubitemid 350100810)
50. Tempone AG, Mortara RA, de Andrade Jr HF., Reimão JQ. (2010). Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis. Int J Antimicrob Agents 36:159-63.
51. Trubetskoy VS, Whiteman KR, Torchilin VP, Wolf GL. (1998). Massage-induced release of subcutaneously injected liposome encapsulated drugs to the blood. J Control Release 50:13-19. (Pubitemid 28044096)
52. Van Widen ECA. (2003). Freeze-drying of liposomes: theory and practice. Methods Enzymol 367:99-110.
53. Vandome FP, McBrewster AF, Miller J. (2009). Leishmaniasis. 1st ed. Mauritius: Alphascript publishing.
54. Vargas-Gonzalez A, Canto-Lara SB, Damian-Centeno AG, Andrade-Narvaez FJ. (1999). Response of cutaneous leishmaniasis (chiclero's ulcer) to treatment with meglumineantimoniate in southeast Mexico. Am J Trop Med Hyg 61:960-3. (Pubitemid 30084121)
55. Wang T, Deng Y, Geng Y, et al. (2006). Preparation of submicron unilamellar liposomes by freeze-drying double emulsions. Biochim Biophys Acta 1758:222-31. (Pubitemid 44294663)
56. Wang T, Li W, Deng Y, Zou J. (2007). Preparation of submicron unilamellartopotecan-entrapping liposomes by freeze-drying double emulsions. Asian J Pharm Sci 2:68-76.
57. Weldon JS, Munnell JF, Hanson WL, Alving CR. (1983). Liposomal chemotherapy in visceral leishmaniasis: an ultrastructural study of an intracellular pathway. Z Parasitenkd 69:415-24. (Pubitemid 13033491)
58. World Health Organization. (2000). Department of Communicable Disease Surveillance and Response. Chapter 10. Plague In: WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases. WHO/CDS/CSR/ISR/2000.1. Geneva: WHO, 121-7. Available from: http://www.who.int/csr/resources/ publications/surveillance/Leishmaniasis.pdf [last accessed March 2011].
59. Yardley V, Croft SL. (1997). Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 41:752-6. (Pubitemid 27150525)
60. Zeisig R, Eue I, Kosch M, et al. (1996a). Preparation and properties of sterically stabilized hexadecylphosphocholine (miltefosine)-liposomes and influence of this modification on macrophage activation. Biochim Biophys Acta 1283:177-84. (Pubitemid 26290711)
61. Zeisig R, Rudolf M, Eue I, Arndt D. (1995). Influence of hexadecylpho-sphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J Cancer Res Clin Oncol 121:69-75.
62. Zeisig R, Shimada K, Hirota S, Arndt D. (1996b). Effect of sterical stabilization on macrophage uptake in vitro and on thickness of the fixed aqueous layer of liposomes made from alkylphosphocholines. Biochim Biophys Acta 1285:237-45. (Pubitemid 26403082)